Surface Plasmon Resonance as an Analytical Tool for Bioprocessing - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Surface Plasmon Resonance as an Analytical Tool for Bioprocessing
A Q&A with GE Healthcare

Pharmaceutical Technology
Volume 34, pp. s2-s3

PharmTech: What are the advantages of SPR over existing analytic technologies?

Sundberg: Because SPR detects binding in real time, and sample prep is minimal, there's a tremendous time-saving over, say, ELISA or high-performance liquid chromatograhy. Variability is low, and the coefficient of variability often falls in the range of 1–5%, even for very crude samples (e.g., cell-culture supernatants). Apart from the improved productivity, SPR also resolves affinity into its kinetic parameters (on-and off-rates) which enables scientists to assess more clinically relevant parameters such as recognition and stability of binding to target-binding site.

PharmTech: Could you give us an idea of what sort of time saving you're talking about?

Sundberg: You would get an answer from an ELISA assay in a matter of hours, but SPR could give you an answer within a few minutes (3–10 minutes). For process engineers, this can shave considerable time off process development. Also, unlike HPLC, SPR does not require you to produce a standard curve, so that essentially SPR enables calibration-free concentration analysis. This is of great advantage when you have an unstable standard, or if a standard is not available.

PharmTech: What is the future potential of SPR as a PAT tool?

Sundberg: The real-time capability and critical information from SPR would provide a great advantage in PAT applications in the future. On-line or in-line detection of product with SPR would provide critical information of quality attributes and how these are affected by process modifications. For example, there have been some academic initiatives that have proven the possibility of connecting Biacore to bioreactors for continuous monitoring of expression levels over time under various conditions.


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Obama Administration Halts Attack on Medicare Drug Plans
Source: Pharmaceutical Technology,
Click here